Recombinant human thrombopoietin - 3SBio

Drug Profile

Recombinant human thrombopoietin - 3SBio

Alternative Names: rHuTPO - 3SBio; Tpiao

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator 3SBio
  • Class Colony-stimulating factors; Glycoproteins
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Preclinical Aplastic anaemia

Most Recent Events

  • 16 Sep 2016 Preclinical trials in Aplastic anaemia in China (Parenteral) before September 2016 (3SBio pipeline, September 2016)
  • 16 Sep 2016 3SBio files an IND application with the C FDA in China for Aplastic anaemia (3SBio pipeline, September 2016)
  • 03 Nov 2011 Launched for Thrombocytopenia in Philippines (SC) prior to November 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top